Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 10, 2025 • 3:01 PM ET

Date/Time Source News Release
06/06/2025 09:39 AM EDT GlobeNewswire Immix Biopharma Attends FDA CEO Forum in Washington DC
06/03/2025 02:55 PM EDT GlobeNewswire Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
05/23/2025 09:05 AM EDT GlobeNewswire Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
05/22/2025 04:02 PM EDT GlobeNewswire Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
05/21/2025 04:03 PM EDT GlobeNewswire Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
04/23/2025 10:04 AM EDT GlobeNewswire Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
02/10/2025 09:35 AM EST GlobeNewswire Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
01/07/2025 09:34 AM EST GlobeNewswire Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
12/19/2024 09:35 AM EST GlobeNewswire Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
12/16/2024 09:48 AM EST GlobeNewswire Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Page

Additional News

As of June 10, 2025 • 3:01 PM ET

Date/Time Source News Release
06/06/2025 12:00 PM EDT Zacks Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
05/08/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, May 8th, 2025
05/08/2025 05:31 AM EDT US Earnings Reports Expected earnings - Immix Biopharma Inc.
03/26/2025 05:30 AM EDT US Earnings Reports Expected earnings - Immix Biopharma Inc.
11/27/2024 04:30 AM EST US Earnings Reports Expected earnings - Immix Biopharma Inc.
08/19/2024 12:00 PM EDT Zacks What Makes Immix Biopharma (IMMX) a New Buy Stock
08/12/2024 10:52 PM EDT InvestorPlace IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024
07/08/2024 02:04 PM EDT SeekingAlpha Immix Biopharma doses first patient in U.S. AL amyloidosis trial
07/03/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Wed, Jul 03, 2024 as of 4:00 pm ET
05/13/2024 09:53 AM EDT InvestorPlace IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.